• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-24

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, better recapitulating the in vivo tumor microenvironment. The platform enables nuanced investigation of tumor–stroma interactions, drug response variability, and resistance mechanisms, advancing personalized cancer research.

• Applied Cancer Research with JNJ-26854165 (Serdemetan): Work

  2026-05-23

  JNJ-26854165 (Serdemetan) enables precise p53 pathway modulation, making it a standout anti-proliferative agent and apoptosis inducer in cancer research. This guide delivers actionable workflows, advanced applications, and troubleshooting insights for maximizing reproducibility and translational value.

• Tacrine Hydrochloride Hydrate: Advanced Mechanisms and Multi

  2026-05-22

  Explore the multifaceted role of Tacrine hydrochloride hydrate in Alzheimer’s disease research, including its unique mechanism as a dual-site cholinesterase inhibitor and scaffold for next-generation multi-target therapeutics. This article provides expert analysis, protocol insights, and critical evaluation of the latest innovations in neurodegenerative disease modeling.

• ML385: Precision NRF2 Inhibitor Workflows for Cancer Researc

  2026-05-22

  ML385 enables rigorous, pathway-specific inhibition of NRF2, empowering cancer researchers to dissect therapeutic resistance and oxidative stress mechanisms with unmatched selectivity. This guide details advanced protocols, troubleshooting insights, and translational applications—making ML385 the go-to NRF2 inhibitor for both in vitro and in vivo studies.

• (Z)-4-Hydroxytamoxifen: Unraveling Tumor Relapse in Breast C

  2026-05-21

  (Z)-4-Hydroxytamoxifen, a potent estrogen receptor modulator, enables advanced modeling of breast cancer relapse and resistance. This article uniquely explores its integration in state-of-the-art genetic mouse models, illuminating how cutting-edge proliferation tracing transforms preclinical research.

• Hypoxia and Immunometabolism in Tumor Microenvironments

  2026-05-21

  This review dissects the mechanisms by which tumor hypoxia and immunometabolic reprogramming shape the tumor microenvironment (TME), emphasizing their roles in immune evasion and tumor progression. The article provides a detailed synthesis of how metabolic competition and adaptation among cancer and immune cells underpin both disease evolution and opportunities for targeted interventions.

• ML385 NRF2 Inhibitor: Precision Tools for Redox and Cancer R

  2026-05-20

  ML385 is an advanced, selective NRF2 inhibitor that enables researchers to dissect antioxidant pathways in cancer, inflammation, and osteolytic disease models. Its proven efficacy for modulating therapeutic resistance and mechanistic redox signaling sets the standard for translational research and protocol optimization.

• G007-LK Tankyrase 1/2 Inhibitor: Precision in Cancer Pathway

  2026-05-20

  G007-LK is a nanomolar-potency tankyrase 1/2 inhibitor that provides robust, reproducible suppression of Wnt/β-catenin signaling and β-catenin degradation. This guide delivers actionable workflow enhancements, troubleshooting strategies, and real-world protocol optimizations for APC mutation colorectal cancer and Hippo pathway research.

• Asunaprevir (BMS-650032): Strategic Leverage in HCV Research

  2026-05-19

  This thought-leadership article explores Asunaprevir (BMS-650032) as a versatile, mechanistically distinct tool for translational hepatitis C research. It integrates biochemical and pharmacological insights with advanced protocol recommendations and comparative analysis, positioning Asunaprevir as foundational for next-generation studies on HCV RNA replication inhibition and host-pathogen dynamics. Visionary guidance is offered for researchers seeking to bridge virology, epigenetics, and translational models, with strategic navigation of the evolving antiviral landscape.

• ML385: Precision NRF2 Inhibitor for Oxidative Stress & Cance

  2026-05-19

  ML385 stands out as a selective NRF2 inhibitor, enabling researchers to dissect antioxidant signaling and therapeutic resistance at unprecedented resolution. Its robust performance in both cell-based and in vivo models makes it an indispensable tool for cancer and inflammation studies, with clear protocols and troubleshooting strategies to ensure reproducibility.

• Network Medicine Reveals Apigenin’s Neuroprotective Potentia

  2026-05-18

  A recent study applies a network medicine framework to systematically identify flavonoid candidates for Alzheimer’s disease, highlighting Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) as a top neuroprotective agent. Experimental validation confirms Apigenin’s ability to modulate cell apoptosis and neuroinflammation, suggesting translational promise for neurodegeneration research.

• GSTA1 Drives Glutathione Depletion in α-Amanitin Hepatotoxic

  2026-05-18

  The referenced study reveals that GSTA1, a hepatic detoxification enzyme, paradoxically exacerbates α-amanitin-induced liver injury by accelerating glutathione depletion and oxidative stress. These insights reposition GSTA1 as a mechanistic driver and potential therapeutic target in acute hepatotoxicity, with implications for biomarker discovery and intervention strategies.

• hly Gene Deletion Impairs Biofilm Formation in Listeria mono

  2026-05-17

  This study reveals that deletion of the hly gene in Listeria monocytogenes significantly impairs biofilm formation and increases susceptibility to certain antibiotics. The findings highlight the gene's pivotal regulatory role in virulence, biofilm structure, and antibiotic resistance, providing a foundation for new intervention strategies in food safety and clinical microbiology.

• Moxifloxacin as a Precision Probe: Decoding DNA Gyrase and C

  2026-05-16

  Explore how Moxifloxacin, a potent fluoroquinolone antibiotic, enables advanced research into DNA gyrase inhibition, metabolic responses, and cytotoxicity. This article delivers mechanistic clarity and assay guidance grounded in recent structural biology breakthroughs.

• Machine Learning Predicts Lipid Nanoparticle Efficacy for mR

  2026-05-15

  This study introduces a machine learning framework for predicting the efficacy of lipid nanoparticle (LNP) formulations in mRNA vaccine delivery. By integrating experimental data with LightGBM modeling, the work advances rational LNP design, streamlining the identification of high-performing ionizable lipids such as SM-102 and MC3.

400 records 7/27 page Previous Next First page 上5页 678910 下5页 Last page